Apellis Pharmaceuticals Newsroom

Apellis Pharmaceuticals (APLS) Gets a Hold From Mizuho Securities

TipRanksSep 16 14:29

Apellis Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow JonesSep 14 03:34

Apellis Pharmaceuticals Analyst Ratings

BenzingaSep 14 03:25

J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57

Futu NewsSep 13 08:31

BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61

Futu NewsSep 10 00:31

Apellis Pharmaceuticals Analyst Ratings

BenzingaAug 13 20:34

JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $64

BenzingaAug 13 20:33

J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $64

Futu NewsAug 13 20:31

Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)

TipRanksAug 12 19:16

Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

TipRanksAug 9 21:36

Apellis Pharmaceuticals Analyst Ratings

BenzingaAug 9 18:32

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

BenzingaAug 9 18:32

Buy Rating Affirmed on Apellis Pharmaceuticals Amid Empaveli's Strong Clinical Outcomes and Market Potential

TipRanksAug 9 00:18

Buy Rating Affirmed for Apellis Pharmaceuticals Amid Competitive Market Dynamics and Growth Potential

TipRanksAug 5 14:31

HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $83

BenzingaAug 3 05:22

Oppenheimer Initiates Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $65

Futu NewsAug 3 01:31

Apellis Pharmaceuticals Price Target Cut to $66.00/Share From $77.00 by Goldman Sachs

Dow JonesAug 3 00:35

A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $48 to $95

Futu NewsAug 2 21:03

Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know

BenzingaAug 2 20:03

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

BenzingaAug 2 18:54